secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001104659-22-115713
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics completes acquisition of Baergic Bio and its CNS asset BAER-101
--------------------------------------------------------------------------------

- Acquired majority of Baergic Bio shares from Fortress Biotech; Baergic now a subsidiary of Avenue.
- Baergic's lead compound BAER-101 is a selective GABA-A α2/3 PAM in-licensed from AstraZeneca with safety data in over 700 patients.
- Closing conditions included $7.5M equity raise and repurchase of InvaGen's shares in Avenue.
- CEO Alexandra MacLean said BAER-101 has potential for orphan and larger CNS indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000110465922115713/0001104659-22-115713-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000110465922115713/tm2229538d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-115713

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer